Back to Search
Start Over
Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report.
- Source :
-
Hospital pharmacy [Hosp Pharm] 2021 Dec; Vol. 56 (6), pp. 640-645. Date of Electronic Publication: 2020 Sep 08. - Publication Year :
- 2021
-
Abstract
- In 2019, a novel coronavirus was identified in Wuhan, China. This strain was classified as a pandemic in early 2020 by the World Health Organization (WHO), rapidly reaching millions of cases worldwide and overwhelming intensive care units. One distinct feature identified in severe SARS-CoV-2 is abnormal and complex coagulation and hematologic abnormalities, including significantly elevated D-dimer and fibrin/fibrinogen values possibly increasing morbidity and mortality in this patient population. Aggressive anticoagulation therapy with appropriate peak anti-Xa level monitoring has produce satisfactory results at our institution. Our intent is to present a case series of our strategy to highlight the benefits of this approach.<br />Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.<br /> (© The Author(s) 2020.)
Details
- Language :
- English
- ISSN :
- 0018-5787
- Volume :
- 56
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Hospital pharmacy
- Publication Type :
- Academic Journal
- Accession number :
- 34732915
- Full Text :
- https://doi.org/10.1177/0018578720954154